Agree that ALA valuation is ridiculous. Well ours is more ridiculous.
But it is incorrect to state that we are the only company in the world looking to treat solid tumours, or even gastrointestinal cancers specifically, using CAR-T or other cell therapies.
There are HEAPS of CAR-Ts and other cell therapies in development for solid tumours including gastrointestinal, many already completing clinical trials amd getting promising results.
Even for GBM, there are at least a dozen CAR-T products in clinical trials.
CHM assets are unlikely to be first-in-class. But maybe best-in-class.
CHM Price at posting:
1.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)